At a glance
- Originator Aventis
- Class Antineoplastics; Small molecules
- Mechanism of Action Aromatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 29 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma
- 15 Nov 1994 Preclinical development for Breast cancer in France (Unknown route)